The Budesonide in Babies (BiB) Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,160

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

September 5, 2024

Study Completion Date

December 17, 2026

Conditions
Bronchopulmonary Dysplasia (BPD)Respiratory Distress SyndromePrematurity; ExtremeNeonatal
Interventions
DRUG

budesonide (Pulmicort nebulizing suspension).

The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.

DRUG

surfactant (poractant alfa;Curosurf)

The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.

Trial Locations (19)

14642

University of Rochester, Rochester

19104

University of Pennsylvania, Philadelphia

27705

RTI International, Durham

27710

Duke University, Durham

30303

Emory University, Atlanta

39216

University of Mississippi Medical Center - Children's of Mississippi, Jackson

43205

Research Institute at Nationwide Children's Hospital, Columbus

44106

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland

45267

Cincinnati Children's Medical Center, Cincinnati

52242

University of Iowa, Iowa City

60611

Northwestern Lurie Children's Hospital of Chicago, Chicago

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

77030

University of Texas Health Science Center at Houston, Houston

84108

University of Utah, Salt Lake City

87131

University of New Mexico, Albuquerque

92123

Sharp Mary Birch Hospital for Women & Newborns, San Diego

94304

Stanford University, Palo Alto

35249-7335

University of Alabama, Birmingham

02905

Brown University - Women and Infants Hospital of Rhode Island, Providence

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

NICHD Neonatal Research Network

NETWORK

NCT04545866 - The Budesonide in Babies (BiB) Trial | Biotech Hunter | Biotech Hunter